Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors

被引:11
|
作者
Ikuta, Kunihiro [1 ]
Urakawa, Hiroshi [1 ]
Kozawa, Eiji [1 ]
Arai, Eisuke [1 ]
Zhuo, Lisheng [2 ]
Futamura, Naohisa [1 ]
Hamada, Shunsuke [1 ]
Kimata, Koji [2 ]
Ishiguro, Naoki [1 ]
Nishida, Yoshihiro [1 ]
机构
[1] Nagoya Univ, Dept Orthopaed Surg, Grad Sch & Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Aichi Med Univ, Nagakute, Aichi 48011, Japan
关键词
Malignant peripheral nerve sheath tumors; Hyaluronan; Neurofibroma; Prognostic factor; SYNTHASE EXPRESSION; OVARIAN-CANCER; CELLS; RETENTION; SURVIVAL; INSTITUTION; INHIBITION; CARCINOMA; PROMOTES; GROWTH;
D O I
10.1007/s10585-014-9662-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hyaluronan (HA) regulates malignant tumor growth, invasion, and metastasis. However, few studies have focused on the roles of HA in tumorigenicity in malignant peripheral nerve sheath tumors (MPNST). In this study, we sought to clarify the prognostic value of HA in patients with MPNST. Specimens obtained from 15 patients with neurofibroma and 30 with MPNST were subjected to HA staining and scored as three grades. Protein expressions of HA synthase 1-3 were examined in the 22 MPNST tissue samples available. Statistically higher HA positivity was observed in MPNST as compared with neurofibroma (P = 0.020). The univariate analysis revealed that increased HA expression, age, neurofibromatosis type 1 (NF1) status, large tumor size, and histological grade were significantly associated with reduced overall survival of patients with MPNST; while increased HA expression, NF1 status, tumor size, and histological grade were correlated with disease-free survival. However, HA synthase 1-3 expression related to neither overall survival nor disease-free survival of these patients. In multivariate analysis, large tumor size (P = 0.022) was an independent prognostic factor for overall survival, and HA expression (P = 0.028) and tumor size (P = 0.002) were independent prognostic factors for disease-free survival. Statistically higher levels of HA in the human MPNST cells were observed compared with neurofibroma cells in vitro. Our results demonstrate that HA expression can be a useful marker in differentiating MPNST from neurofibroma, and in identifying patients with a poor prognosis. Hyaluronan-targeting therapy for patients with MPNST may have potential as a therapeutic tool.
引用
收藏
页码:715 / 725
页数:11
相关论文
共 50 条
  • [1] Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors
    Kunihiro Ikuta
    Hiroshi Urakawa
    Eiji Kozawa
    Eisuke Arai
    Lisheng Zhuo
    Naohisa Futamura
    Shunsuke Hamada
    Koji Kimata
    Naoki Ishiguro
    Yoshihiro Nishida
    Clinical & Experimental Metastasis, 2014, 31 : 715 - 725
  • [2] Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance
    Venturini, Lorenza
    Daidone, Maria Grazia
    Motta, Rosita
    Cimino-Reale, Graziella
    Hoare, Stacey F.
    Gronchi, Alessandro
    Folini, Marco
    Keith, William Nicol
    Zaffaroni, Nadia
    NEURO-ONCOLOGY, 2012, 14 (06) : 736 - 744
  • [3] Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors
    Jia, Xiaotian
    Chen, Chao
    Chen, Lin
    Yu, Cong
    Kondo, Tadashi
    ONCOLOGY LETTERS, 2019, 17 (03) : 3517 - 3522
  • [4] Malignant Peripheral Nerve Sheath Tumors
    Khu, Kathleen Joy
    Midha, Rajiv
    WORLD NEUROSURGERY, 2016, 94 : 566 - 567
  • [5] Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST)
    Alaggio, Rita
    Turrini, Riccardo
    Boldrin, Daniela
    Merlo, Anna
    Gambini, Claudio
    Ferrari, Andrea
    Dall'Igna, Patrizia
    Coffin, Cheryl M.
    Martines, Annalisa
    Bonaldi, Laura
    De Salvo, Gian Luca
    Zanovello, Paola
    Rosato, Antonio
    PLOS ONE, 2013, 8 (11):
  • [6] Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors
    Zhang, Lindy
    Lemberg, Kathryn M.
    Calizo, Ana
    Varadhan, Ravi
    Siegel, Alan H.
    Meyer, Christian F.
    Blakeley, Jaishri O.
    Pratilas, Christine A.
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [7] Therapeutic targets for malignant peripheral nerve sheath tumors
    Wu, Lai Man Natalie
    Lu, Qing Richard
    FUTURE NEUROLOGY, 2019, 14 (01)
  • [8] Aberrant expression of tenascin-c and neuronatin in malignant peripheral nerve sheath tumors
    Dugu, Long
    Hayashida, Sayaka
    Nakahara, Takeshi
    Xie, Lining
    Iwashita, Yayoi
    Liu, Xiguang
    Uchi, Hiroshi
    Tateuchi, Satoshi
    Takahara, Masakazu
    Oda, Yoshinao
    Moroi, Yoichi
    Furue, Masutaka
    EUROPEAN JOURNAL OF DERMATOLOGY, 2010, 20 (05) : 580 - 584
  • [9] Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors
    Pridgeon, Matthew G.
    Grohar, Patrick J.
    Steensma, Matthew R.
    Williams, Bart O.
    CURRENT OSTEOPOROSIS REPORTS, 2017, 15 (04) : 239 - 246
  • [10] Diagnostic and Prognostic Value of CD10 in Peripheral Nerve Sheath Tumors
    Cabibi, Daniela
    Zerilli, Monica
    Caradonna, Giuseppe
    Schillaci, Loredana
    Belmonte, Beatrice
    Rodolico, Vito
    ANTICANCER RESEARCH, 2009, 29 (08) : 3149 - 3155